Denali Therapeutics Inc. · NASDAQ:DNLI

Denali Therapeutics — J.P. Morgan Healthcare Conference 2023

27 slides from Denali Therapeutics's conference presentation, January 2023

  1. Slide 1: Corporate Overview

    Corporate Overview January 2023

  2. Slide 2: Disclaimers

    Disclaimers Forward-Looking Statements. This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements do not relate strictly to historical or current facts and they may be accompanied by such words a

  3. Slide 3: Building Denali to Defeat Degeneration

    BUILDING DENALI TO DEFEAT DEGENERATION Accomplishments to Date Mid-Term Goals (2023-2025) Long-Term Goals Track Record of Invention & Creating Value & Defeating Execution Delivering Medicines Degeneration 10 INDs across 6 indications, Complete 3 - 4 late-stage clinical Commercial portfolio of 7 prog

  4. Slide 4: Our Focus and Strategic Principles

    OUR FOCUS AND STRATEGIC PRINCIPLES OUR FOCUS OUR SCIENTIFIC PRINCIPLES OUR BUSINESS PRINCIPLES Defeat Degeneration Increase Likelihood of Success Create Value Lysosomal Storage Degenogene Broad Diseases Pathways Portfolio Rare Neurodegenerative Diseases (ALS, FTD) Integrated Brain Delivery Global Ca

  5. Slide 5: Our Development Portfolio

    OUR DEVELOPMENT PORTFOLIO DEVELOPMENT STAGE Mid/Late MODALITY TARGET BIOLOGY DRUG CANDIDATE* DISEASE INDICATION IND-Enabling Early Clinical Clinical PARTNER Iduronate Lysosomal DNL310 2-Sulfatase Function (ETV:IDS) MPS II (Hunter) Lysosomal TAK-594/DNL593 Frontotemporal Dementia- PGRN Function (PTV:

  6. Slide 6: Our Strategy: Broad Portfolio in Parallel Development

    OUR STRATEGY: BROAD PORTFOLIO IN PARALLEL DEVELOPMENT COMMON NEURODEGENERATIVE DISEASES RARE NEURODEGENERATIVE DISEASES LYSOSOMAL STORAGE DISEASES (e.g., MPS II, MPS IIIA) (e.g., ALS, FTD) (e.g., Parkinson’s, Alzheimer’s) DRUG CANDIDATE PHASE IN 2023 DRUG CANDIDATE PHASE IN 2023 DRUG CANDIDATE PHASE

  7. Slide 7: Our Vision: Commercial Organization to Serve Patients

    OUR VISION: COMMERCIAL ORGANIZATION TO SERVE PATIENTS >50M patients WW* >$5B per indication >500,000 patients WW* $1-5B per indication >30,000 patients WW* COMMON NEURODEGENERATIVE DISEASES $500M-1B+ per indication RARE NEURODEGENERATIVE DISEASES LYSOSOMAL STORAGE DISEASES (e.g., MPS II, MPS IIIA) (

  8. Slide 8: Our TV Platform for Brain Delivery of Biotherapeutics

    OUR TV PLATFORM FOR BRAIN DELIVERY OF BIOTHERAPEUTICS

  9. Slide 9: Addressing the Challenge of Delivering Therapy to the Brain

    ADDRESSING THE CHALLENGE OF DELIVERING THERAPY TO THE BRAIN The Transport Vehicle (TV) is engineered to deliver efficacious concentrations of biotherapeutics (large molecules) to brain cells via receptor mediated transcytosis Blood Vessel Enzyme + Transport Vehicle Blood-Brain Barrier Transferrin Re

  10. Slide 10: Transport Vehicle Enables Modality-Optimized Brain Delivery

    TRANSPORT VEHICLE ENABLES MODALITY-OPTIMIZED BRAIN DELIVERY Enzyme Transport Vehicle Antibody Transport Vehicle Deliver enzymes to the brain to replace Deliver antibodies in bivalent deficient or missing enzyme activity ETV or bispecific format to the brain ATV Protein Transport Vehicle PTV Oligonuc

  11. Slide 11: TV Platform Opportunities Drive Sustainable Value Creation

    TV PLATFORM OPPORTUNITIES DRIVE SUSTAINABLE VALUE CREATION Each TV modality is a platform opportunity FUTURE PROGRAM ETV:GCase TV PLATFORM ETV:ARSA FUTURE DEVELOPMENT PROGRAM PROGRAMS ETV:NAGLU OTV:Epilepsy FUTURE ETV:GAA PROGRAM OTV:UBE3A-ATS ETV:IDUA ATV:HER2 OTV:DMPK FUTURE FUTURE ETV:SGSH ATV:Ab

  12. Slide 12: Denali Therapeutics Inc.

    12 Denali Therapeutics Inc. Confidential

  13. Slide 13: DNL126 (ETV:SGSH): Expands ETV Platform for MPS IIIA

    DNL126 (ETV:SGSH): EXPANDS ETV PLATFORM FOR MPS IIIA Addressing cognitive, behavioral & physical IV DNL126 treatment reduces HS in a dose- manifestations of Sanfilippo syndrome Type A dependent manner in brain and CSF • Rare lysosomal storage disease (LSD) that causes MPS IIIa;TfR KI *** < 0.001 ***

  14. Slide 14: DNL593 (PTV:PGRN): PGRN Brain Delivery for FTD-GRN

    DNL593 (PTV:PGRN): PGRN BRAIN DELIVERY FOR FTD-GRN Brain delivery of progranulin (PGRN) designed to treat frontotemporal dementia-granulin (FTD-GRN) • FTD is the most common dementia in people under 60; no approved therapies • FTD-GRN is associated with progranulin (PGRN) deficiency; accounts for 5-

  15. Slide 15: ATV: Targeting TREM2 and Abeta for Alzheimer's Disease

    ATV: TARGETING TREM2 AND ABETA FOR ALZHEIMER’S DISEASE (AD) ATV enables significantly improved target engagement in mice, which may improve the therapeutic window ATV:TREM2 shifts most microglia to responsive states ATV:Abeta shows broad parenchymal plaque binding compared to standard anti-TREM2 in

  16. Slide 16: OTV Is Designed to Enhance CNS Delivery of Oligonucleotides

    OTV IS DESIGNED TO ENHANCE CNS DELIVERY OF OLIGONUCLEOTIDES Therapeutic oligonucleotides have the potential OTV has potential to revolutionize to address challenging targets ASOs/oligos for treating CNS disease • Oligonucleotide Transport Vehicle (OTV) is designed to: - Enable superior biodistributi

  17. Slide 17: OTV Provides Uniform ASO Deposition Across the CNS with IV Delivery

    OTV PROVIDES UNIFORM ASO DEPOSITION ACROSS THE CNS WITH IV DELIVERY NAKED ASO INTRATHECAL (IT) DELIVERY OTV INTRAVENOUS (IV) DELIVERY Limited ASO Biodistribution Widespread ASO Biodistribution BRAIN BRAIN ANTERIOR POSTERIOR ANTERIOR POSTERIOR SPINAL CORD SPINAL CORD 17 anti-ASO ©2023 Denali Therapeu

  18. Slide 18: OTV Provides Uniform ASO Deposition Across the CNS with IV Delivery

    OTV PROVIDES UNIFORM ASO DEPOSITION ACROSS THE CNS WITH IV DELIVERY NAKED ASO INTRATHECAL (IT) DELIVERY OTV INTRAVENOUS (IV) DELIVERY Limited ASO Biodistribution Widespread ASO Biodistribution CORTEX STRIATUM CORTEX STRIATUM CEREBELLUM WHITE MATTER CEREBELLUM WHITE MATTER 18 anti-ASO ©2023 Denali Th

  19. Slide 19: OTV Enables More Uniform Knockdown of Target Gene Expression

    OTV ENABLES MORE UNIFORM KNOCKDOWN OF TARGET GENE EXPRESSION NAKED ASO INTRATHECAL (IT) DELIVERY OTV INTRAVENOUS (IV) DELIVERY Data represented as mean +/- SEM; n=3 IV OTV shows uniform knockdown across the CNS compared to IT ASO 19 ©2023 Denali Therapeutics Inc. All rights reserved.

  20. Slide 20: OTV Target Selection

    OTV TARGET SELECTION TARGET INDICATION PREVALENCE DIFFERENTIATION STRATEGY COMMON NEURODEGENERATIVE DISEASES MAPT Alzheimer’s Disease 6-10M cases US Uniform knockdown of MAPT across the CNS to effectively reduce all forms of Tau protein & decrease aggregates SNCA Parkinson’s Disease 1M cases US Unif

  21. Slide 21: Our Brain-Penetrant Small Molecule Programs

    OUR BRAIN-PENETRANT SMALL MOLECULE PROGRAMS

  22. Slide 22: BIIB122 (LRRK2 Inhibitor): Targeting the Lysosome in PD

    BIIB122 (LRRK2 INHIBITOR): TARGETING THE LYSOSOME IN PD Targeting LRRK2 may impact the underlying Rigorous development program to evaluate BIIB122 biology and slow the progression of PD in patients with and without LRRK2 mutations Phase 2b Phase 3 • 10M+ people with Parkinson’s disease (PD) WW LUMA

  23. Slide 23: DNL343 (eIF2B Activator): Inhibiting the ISR Pathway in ALS

    DNL343 (eIF2B ACTIVATOR): INHIBITING THE ISR PATHWAY IN ALS By inhibiting the ISR pathway, DNL343 is 28-day dosing with DNL343 reduced ISR intended to prevent or slow ALS progression biomarkers in blood samples* from ALS patients (interim Phase 1b data) • ~250,000 people with ALS WW ATF4 protein lev

  24. Slide 24: RIPK1 Inhibitors: Targeting Inflammation and Cell Death

    RIPK1 INHIBITORS: TARGETING INFLAMMATION AND CELL DEATH RIPK1 is a critical signaling protein in a canonical 93% to 99% RIPK1 inhibition achieved in Phase 1 inflammatory and cell death pathway after multiple doses of SAR443820* • Increased RIPK1 activity drives neuroinflammation RIPK1 (Mean Percent

  25. Slide 25: Our Priorities

    OUR PRIORITIES Commercial 1 Clinical Execution 2 TV Expansion 3 Readiness • 4 late-stage programs enrolling • Clinical data expected from 3 • Define go-to-market strategies in studies in MPS II, ALS, and PD TV-platform enabled programs the US and key global markets • Multiple earlier-stage trials •

  26. Slide 26: Our Purpose: Defeat Degeneration

    OUR PURPOSE: DEFEAT DEGENERATION Thank you to all those who are part of Denali’s purpose, especially our patients and their families LYSOSOMAL STORAGE RARE NEURODEGENERATIVE PARKINSON’S ALZHEIMER’S DISEASE DISEASES (ALS, FTD) DISEASE DISEASE Denali The name captures the formidable challenges in figh

  27. Slide 27: Thank You

    THANK YOU

Denali Therapeutics — J.P. Morgan Healthcare Conference 2023 on 6ix